Pathstone Family Office LLC Has $1.73 Million Stake in STERIS plc (NYSE:STE)

Pathstone Family Office LLC increased its position in shares of STERIS plc (NYSE:STEFree Report) by 62.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,904 shares of the medical equipment provider’s stock after purchasing an additional 3,037 shares during the quarter. Pathstone Family Office LLC’s holdings in STERIS were worth $1,734,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of STE. 9258 Wealth Management LLC lifted its holdings in shares of STERIS by 15.7% in the third quarter. 9258 Wealth Management LLC now owns 1,364 shares of the medical equipment provider’s stock worth $299,000 after acquiring an additional 185 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in shares of STERIS by 10.6% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 6,588 shares of the medical equipment provider’s stock worth $1,446,000 after acquiring an additional 632 shares during the last quarter. Van ECK Associates Corp lifted its holdings in shares of STERIS by 13.4% in the third quarter. Van ECK Associates Corp now owns 12,042 shares of the medical equipment provider’s stock worth $2,642,000 after acquiring an additional 1,424 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in shares of STERIS by 1.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 513,113 shares of the medical equipment provider’s stock worth $112,587,000 after acquiring an additional 5,167 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its holdings in shares of STERIS by 8.9% in the third quarter. Sequoia Financial Advisors LLC now owns 2,862 shares of the medical equipment provider’s stock worth $628,000 after acquiring an additional 234 shares during the last quarter. Institutional investors own 92.91% of the company’s stock.

Analyst Upgrades and Downgrades

STE has been the subject of a number of research reports. Morgan Stanley dropped their target price on shares of STERIS from $225.00 to $215.00 and set an “equal weight” rating for the company in a report on Monday, December 4th. KeyCorp started coverage on STERIS in a research note on Tuesday, February 6th. They issued an “overweight” rating and a $253.00 price objective for the company. Stephens reaffirmed an “overweight” rating and issued a $250.00 price objective on shares of STERIS in a research note on Friday. TheStreet raised STERIS from a “c+” rating to a “b” rating in a research note on Wednesday. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research note on Thursday. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $239.60.

Read Our Latest Report on STERIS

STERIS Stock Performance

NYSE:STE opened at $224.27 on Monday. The company has a market capitalization of $22.16 billion, a PE ratio of 39.28 and a beta of 0.80. The company has a 50 day simple moving average of $216.56 and a two-hundred day simple moving average of $218.28. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.49 and a current ratio of 2.43. STERIS plc has a fifty-two week low of $173.21 and a fifty-two week high of $254.00.

STERIS (NYSE:STEGet Free Report) last released its earnings results on Wednesday, February 7th. The medical equipment provider reported $2.22 earnings per share for the quarter, beating analysts’ consensus estimates of $2.17 by $0.05. The business had revenue of $1.40 billion during the quarter, compared to the consensus estimate of $1.35 billion. STERIS had a net margin of 10.48% and a return on equity of 13.67%. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.02 EPS. Research analysts anticipate that STERIS plc will post 8.67 earnings per share for the current year.

STERIS Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 22nd. Shareholders of record on Friday, February 23rd will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 0.93%. The ex-dividend date of this dividend is Thursday, February 22nd. STERIS’s payout ratio is 36.43%.

About STERIS

(Free Report)

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.

Recommended Stories

Want to see what other hedge funds are holding STE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STERIS plc (NYSE:STEFree Report).

Institutional Ownership by Quarter for STERIS (NYSE:STE)

Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.